Who are OSE2101's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CPA, VEC, D-cure, MR-Vac, PANVAC™-VF, MSB0010718C.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ose2101.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

OSE2101 — Competitive Intelligence Brief

OSE2101 (OSE2101) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Therapeutic cancer vaccine. Area: Oncology.

phase 3 Therapeutic cancer vaccine WT1 (Wilms tumor antigen 1) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

OSE2101 (OSE2101) — GERCOR - Multidisciplinary Oncology Cooperative Group. OSE2101 is a therapeutic cancer vaccine that targets WT1 (Wilms tumor antigen 1) to activate the immune system against WT1-expressing tumor cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
OSE2101 TARGET	OSE2101	GERCOR - Multidisciplinary Oncology Cooperative Group	phase 3	Therapeutic cancer vaccine	WT1 (Wilms tumor antigen 1)
CPA	CPA	ImmunoVaccine Technologies, Inc. (IMV Inc.)	marketed	Therapeutic cancer vaccine
VEC	VEC	Centre Leon Berard	marketed	Therapeutic cancer vaccine
D-cure	D-cure	KU Leuven	marketed	Therapeutic cancer vaccine
MR-Vac	MR-Vac	GlaxoSmithKline	phase 3	Therapeutic cancer vaccine
PANVAC™-VF	PANVAC™-VF	Therion Biologics Corporation	phase 3	Therapeutic cancer vaccine	ras and CEA (carcinoembryonic antigen)
MSB0010718C	MSB0010718C	Istituto Oncologico Veneto IRCCS	phase 3	Therapeutic cancer vaccine	Patient-specific tumor neoantigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Therapeutic cancer vaccine class)

GlaxoSmithKline · 2 drugs in this class
Green Cross Corporation · 2 drugs in this class
Chiang Mai University · 1 drug in this class
Chiltern Pesquisa Clinica Ltda · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Galena Biopharma, Inc. · 1 drug in this class
Genocea Biosciences, Inc. · 1 drug in this class
ImmunoVaccine Technologies, Inc. (IMV Inc.) · 1 drug in this class
Istituto Oncologico Veneto IRCCS · 1 drug in this class
KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OSE2101 — Competitive Intelligence Brief. https://druglandscape.com/ci/ose2101. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab